AnaSpec Introduces Extensive Line of Caspase Substrates and Inhibitors
Date Posted: Friday, September 08, 2006
AnaSpec has announced that it provides premier custom services including peptide synthesis, antibody production, and assay development.
AnaSpec holds a California Drug Manufacturing License (License #41747) and a FDA Registration for GMP Drug Manufacturing (Registration #2951078).
Caspases are a family of cysteine-dependent aspartate specific proteases involved in the destruction of cells. In a normal, healthy human being, damaged or mutated cells are regularly destroyed to protect the rest of the body.
The induction of caspase-dependent programmed cell death triggers a tightly-controlled cascade of events with the initiator caspases activating effector caspases.
AnaSpec claims that, these effector caspases not only activate other effector caspases and provide feedback to initiator caspases, they also cleave cellular substrates resulting in morphological changes such as DNA fragmentation, membrane blebbing or apoptotic body formation.
These changes, characteristics of apoptosis, ultimately lead to the death of a cell.
Caspases, however, may not be the only enzymes involved in cell death; cell death may still occur even if all caspases are all blocked.
Because of their important role in apoptosis and cell signaling, and their identification as drug-screening targets, there is a recognized need for a wide range of caspase substrates and inhibitors.
AnaSpec has introduced an extensive list of caspase substrates (including both chromogenic and fluorogenic variations) and caspase inhibitors.
Further Information: http://www.anaspec.com/
Request Information From Vendor
AnaSpec Introduces HTS-Optimized EnzoLyte™ Caspase Assay Kits
EnzoLyte™ Homogeneous Caspase-3/7 Assay Kits detects caspase 3/7 activity in cells.
Related news from our archive
Dr. Rich Meyer Joins AnaSpec to Lead Detection Reagents Division
Meyer is responsible for strengthening the product development strategy of AnaSpec’s detection reagents division.